Reported by 1 source

The short version

  • Scientists used CRISPR technology to disable the Can f 1 allergen gene in two beagles, resulting in animals that did not trigger allergic reactions in testing.
  • The study suggests a viable method for creating hypoallergenic companion animals, though other allergens exist and long-term health effects are still being monitored.
  • Commercial availability is delayed pending FDA approval, while experts debate the ethical implications of genetic modification versus traditional breeding practices.

A new development in genetic engineering may soon allow individuals with dog allergies to own pets without suffering from typical symptoms. Researchers at Kindred Companion Sciences have successfully created two beagles, named Alfie and Bailey, that lack a primary protein responsible for triggering allergic reactions in humans. The team utilized CRISPR, a precise DNA-editing tool, to disable the gene coding for Can f 1, a common allergen found in dog saliva and dander.

The process involved extracting skin cells from a beagle, editing the specific genes within those cells, and then cloning them. These altered cells were inserted into donated egg cells to create reconstructed embryos. Twenty-five such embryos were implanted into a surrogate beagle, which gave birth to Alfie and Bailey in September 2024. The resulting puppies appear physically identical to standard members of their breed but possess a modified genetic makeup designed to reduce allergenicity.

News Journal

Testing conducted by the research team indicates that the gene editing was effective. Samples of saliva and dander from Alfie and Bailey showed no traces of the Can f 1 protein. In contrast, samples from a regular beagle, as well as from a poodle and a goldendoodle—breeds often marketed as hypoallergenic—did contain the allergen. Skin-prick tests performed on Matt Walker, the company’s CEO and a geneticist who suffers from dog allergies, confirmed that extracts from the gene-edited dogs did not elicit an allergic response, whereas samples from the other breeds did.

Walker, who co-founded Kindred Companion Sciences after being unable to own a dog due to his own sensitivities, has lived with Bailey for approximately eighteen months without experiencing reactions. This personal success story underscores the practical potential of the technology. However, the researchers emphasize that this is an early stage in development. The team is closely monitoring the health of Alfie and Bailey to ensure that the genetic alterations have not caused any unforeseen medical issues or developmental problems.

The broader implications of this research extend beyond these two specific animals. The goal is to establish a line of 'founder animals' that can breed naturally, passing on the hypoallergenic trait to future generations. Because the DNA edit is present in every cell derived from the original embryos, mating two edited animals should result in offspring that also carry the modification. This approach aims to create a sustainable population of companion animals suitable for allergy sufferers.

Despite the scientific success, significant hurdles remain before such dogs can be available to the public. The genetic modifications have not yet received approval from the Food and Drug Administration, a necessary step for commercial distribution. Furthermore, experts note that disabling Can f 1 does not guarantee a complete solution for all allergy sufferers. Other proteins, such as Can f 2, can also induce allergic symptoms, meaning some individuals may still react to these gene-edited dogs.

The introduction of gene-edited pets has sparked ethical discussions within the scientific and bioethical communities. Arthur Caplan, a bioethicist at New York University, noted that while this technology could expand pet ownership opportunities, it might also discourage adoption from shelters where unmodified animals are available. Conversely, Alison Van Eenennaam, an animal genetics expert at UC Davis, suggested that the ethical concerns are not unique to genetic engineering but are similar to those associated with traditional selective breeding practices aimed at producing specific traits in companion animals.

This work follows a similar precedent set in feline genetics. Approximately two and a half years ago, researchers reported creating Alsik, a domestic cat edited to reduce levels of the Fel d 1 allergen. However, unlike the current canine research which is moving toward potential commercialization pending regulatory review, gene-edited cats like Alsik are not currently available to consumers. The progress with beagles marks a distinct step forward in applying genetic tools to improve the compatibility between humans and their animal companions.

As Kindred Companion Sciences continues its work, the focus remains on careful and responsible development. The company aims to build toward a next generation of companion animals that are safer for allergy sufferers while maintaining the health and well-being of the dogs themselves. Until regulatory bodies provide clearance and further long-term studies confirm safety, these gene-edited beagles will remain part of a controlled research environment rather than a consumer product.

Sources behind this briefing

Go to the original reporting

  • Smithsonian Magazine↗Allergic to Dogs? These Gene-Edited Beagles Could Pave the Way to Your Dream Canine Companion That Won't Trigger Sniffles